Unlocking the full potential
of highly potent anticancer drugs

Our technology consists in a prodrug polymer approach combining three essential elements:

1. Drug: we work with the most promising HPAPI that did not reach the clinic due to a limited maximal tolerated dose.
2. Polymer: our innovative highly hydrophilic polymer has been tailored to accumulate at the tumor site thanks to its physico-chemical properties.
3. Linker: the polymer prodrug as a whole is inactive and does not induce toxicities. The linker is designed to specifically release the drug into the tumor microenvironment, sparing the healthy tissues.

The combination of these three elements limit the toxicities of the HPAPI and allow increasing the maximal tolerated dose. The improvement of the tumor accumulation increases drug concentration inside the tumor thus leading to a better anticancer effect.

Our solution is unique and beyond the state of the art based on 3 criteria:

1. Our innovative polymer is non toxic (> 10 000 times less toxic than the drug). No risk of toxicities due to the polymer.
2. Our polymers are extremely hydrophilic, we can solubilize even the most insoluble small molecules with short polymer chains. Our vector is smaller than nanoparticles which allows a penetration within the deeper layers of the tumor.
3. Our approach is receptor agnostic compared with the antibody drug conjugate technology. We can address a wide range of cancers and most importantly those that do not express a specific receptor and which are still unmet medical needs.